Wednesday, October 14, 2026

CBOE Bearish Momentum With A 12% Slide In The Last 10 Sessions

ViaNews Editorial Team

September 25, 2024

CBOE Bearish Momentum With A 12% Slide In The Last 10 Sessions

(VIANEWS) - CBOE (VIX) has been up by 12.89% for the last 10 sessions. At 17:08 EST on Wednesday, 25 September, CBOE (VIX) is $15.41.

Regarding CBOE's yearly highs and lows, it's 1.58% up from its 52-week low and 56.03% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a negative 4.41%, a positive 0.21%, and a positive 7.09%, respectively.

CBOE's highest amplitude of average volatility was 4.41% (last week), 7.00% (last month), and 7.09% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CBOE's is considered to be overbought (>=80).

News about

  • According to FXStreet on Monday, 23 September, "Stocks didn't move much on Friday, with the S&P 500 closing 0.19% lower after reaching a new all-time high of 5,733.57 on Thursday. ", "Compared to the previous Friday's close, the S&P 500 gained 1.36%, extending its previous week's rally of 4%. "
  • According to Zacks on Monday, 23 September, "Last week, the S&P 500 gained 1.4%, the tech-focused Nasdaq rose 1.5%, and the Dow Jones Industrial Average climbed 1.6%."
  • According to Zacks on Monday, 23 September, "View all Key Company Metrics for Vail Resorts here>>>Vail Resorts shares have witnessed a change of +4% in the past month, in contrast to the Zacks S&P 500 composite's +2% move. "
  • According to Zacks on Monday, 23 September, "View all Key Company Metrics for Accenture here>>>Accenture shares have witnessed a change of +0.9% in the past month, in contrast to the Zacks S&P 500 composite's +2% move. "
  • According to Zacks on Monday, 23 September, "The stock has declined marginally in the past month against the industry's 4.7% growth and the Zacks S&P 500 composite's 1.6% increase."

More news about CBOE (VIX).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com